Delivery Order SPE2DB22D2211-SPE2DB25FSBAD
- Not listed
- The U.S. Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for Dupixent 300mg/2ml syringes valued at $44,390.30. This competitively awarded, firm fixed-price delivery order is scheduled for completion by August 20, 2025, with performance at the contractor's corporate office location in Conshohocken, Pennsylvania. The award does not utilize a set-aside designation and represents a child contract under AmerisourceBergen's...
- The Defense Logistics Agency awarded a $4,171.54 delivery order to AmerisourceBergen Drug Corp on August 1, 2025, for the supply of Dupixent 200 mg/1.14 mL syringes. This is a firm fixed-price, non-set-aside delivery order with an ultimate completion date of August 4, 2025, and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The delivery order falls under the company's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $1,709.46 for Dupixent 300 mg/2 mL syringes on June 18, 2025, with an ultimate completion date of June 20, 2025. This firm fixed-price, non-set-aside contract was performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a child delivery order issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (contract...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $8,957.42 to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Dupixent 300 mg/2 mL syringes. This non-competitive delivery order, with a firm fixed price structure, represents a child contract against AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The product will be delivered to AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $19,462.69 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml syringes on July 10, 2025, with an ultimate completion date of July 11, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's Conshohocken, Pennsylvania facility. The contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency has awarded a delivery order valued at $9,986.44 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL syringes. This competitively awarded, firm fixed-price contract was issued on August 28, 2025, with an ultimate completion date of August 29, 2025. The product will be supplied from AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a $47,704.56 delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Dupixent 300 mg/2 mL syringes. This is a firm fixed price, non-set-aside contract with an ultimate completion date of August 8, 2025, and represents a child order under AmerisourceBergen's larger contract vehicle with DLA. The pharmaceutical product will be delivered to AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. This delivery order...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order on September 17, 2025, by the Defense Logistics Agency (DLA) for the supply of Dupixent 300 mg/2 mL syringes with a ceiling value of $18,064.58. This is a firm fixed-price delivery order with no set-aside designation, indicating competitive award. The contract has an ultimate completion date of September 18, 2025, and performance will be executed at the...
- The Defense Logistics Agency awarded a delivery order valued at $17,017.67 to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of Dupixent 300 mg/2 mL syringes. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The product will be delivered to AmerisourceBergen's headquarters location...
- The Defense Logistics Agency awarded a delivery order valued at $17,075.52 to AmerisourceBergen Drug Corp for the supply of Dupixent 200 mg/1.14 mL syringes on November 17, 2025. This firm fixed price delivery order, with an ultimate completion date of November 18, 2025, is a non-set-aside award and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract is a child award under AmerisourceBergen's larger Indefinite Delivery Contract (IDC)...
- SPE2DB22D2211Indefinite Delivery Contract
- SPE2DB22D2211-SPE2DB25FSBADDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $1,960.62 to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml syringes on July 17, 2025, with an ultimate completion date of July 18, 2025. This non-set-aside, firm fixed price delivery order was competitively awarded and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 and running through December 2026. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. As a major pharmaceutical distributor headquartered in Pennsylvania, AmerisourceBergen serves as a critical vendor for federal medical procurement, particularly supporting military and veteran healthcare systems. The company's extensive portfolio of federal contracts with the Defense Logistics Agency encompasses a broad range of pharmaceutical products and medical supplies, including specialty medications, brand-name and generic drugs, and medical devices across multiple therapeutic domains. This delivery order for Dupixent, a prescription medication commonly used for immunological conditions, exemplifies the company's role in fulfilling federal medical supply requirements through the DLA's comprehensive pharmaceutical support network.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.0k | 7/17/25 |